Exploiting Controlled Environments for the Development of Optimised Cannabis Sativa Phenotypes for Pharmaceutical Applications - CE-CannPharm

利用受控环境开发用于制药应用的优化大麻表型 - CE-CannPharm

• 批准号: BB/Z514470/1
• 负责人: Derek Stewart
• 金额: $ 44.36万
• 依托单位: James Hutton Institute
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FZ514470%2F1
• 关键词: Exploiting; Controlled; Environments; Development; Optimised

The pharmaceutical industry is relatively mature and underpinned with a plethora of increasing sophisticated science, technology, and more recently, AI approaches. Despite this 90% of clinical drug development fails but global demographic evolution is driving increased numbers of degenerative and neurodegenerative/dysfunctional disease, and this has seen pharma broaden their focus to nature-based therapies and, here, embrace the long-known, and increasingly clinically underpinned, benefits of medicinal cannabis.A recent research briefing from the House of Commons Library report identified that the UK is the world's biggest producer and exporter of legal cannabis for medical and scientific purposes with Prohibition Partners projecting a UK value of £1Bn by 2026 and Statista estimating a global market already in excess of £13Bn in revenue.However, there is a problem with cannabis for the pharmaceutical industry in that the cannabinoid profile changes with location in the plant with the chemo-profiles of the flowers at the top, middle and bottom showing a variance of an order of +/-20% (or more), which is significantly beyond a typical pharmaceutical product tolerance of =+/-10%. This creates a major consistency and grading problem for C.Sativa when it is considered as a pharmaceutical medicine.Here, with our industry partners Glass Pharms Ltd, we aim to address this via several avenues. Via a screen of diverse C.Sativa germplasm we will establish plant architecture variation with the aim of exploring the potential of ultimately creating C.Sativa plants with an altered architecture: less "Christmas tree"- and more "menorah"-shaped, with inflorescence (flowers) more even presented to the incident light. This should impact positively on flower bioactive content composition and importantly variance redcution.We will also look to increase productivity and reduced variance by dwarfing C.Sativa through established methods and exploring the potential of total controlled environmental agriculture here by vertical farming. This absolute control on the environment will allow us to fully exploit the tuneable light intensity and wavelengths of the VF-embedded lights across crop development offering the opportunity to also "tune" the cannabis cannabinoid and terpenoid content, composition and variance. Allied to this we will elucidate the light/plant interactions at the gene and metabolite levels to identify the important gene cascades with a view to identifying gene targets/markers for future exploitation via traditional or modern (genetic modification/gene editing) breeding approaches.Here as part of a collaboration between JHI and Glass Pharms Ltd, both high TCH cannabis production licence holders, we will deliver the following: Greatly improved consistency in the distribution of the active pharmaceutical ingredients contained in Cannabis Sativa across different inflorescence (flowers) on the same plant.Better standardisation of cultivar phenotypes for CAE/VF systems with a target for dwarfed and uniform phenotypes.Defined conditions and process to manipulate/define cannabinoid content and composition. In a wider context the planned research underpins many of the UK policy targets in terms of high-value sector economic growth with associated permanent highly skilled jobs, improvement of healthcare for an evolving demographic and the diversification of the UK agricultural base. The proposed science here will underpin and help maintain the UK's lead as a medicinal cannabis producer and exported.

制药行业相对成熟，并以大量日益复杂的科学、技术和最近的人工智能方法为基础，尽管 90% 的临床药物开发都失败了，但全球人口的演变正在推动退行性和神经退行性/功能障碍性疾病的数量增加。这使得制药公司将他们的关注范围扩大到基于自然的疗法，并在这里拥抱药用大麻的众所周知的、并且在临床上日益得到证实的好处。 下议院图书馆最近的一份研究简报报告指出，英国是世界上最大的用于医疗和科学目的的合法大麻生产国和出口国，Prohibition Partners 预计到 2026 年英国的价值将达到 10 亿英镑，Statista 估计全球市场的收入已超过 130 亿英镑。用于制药工业的大麻，因为大麻素谱随植物中的位置而变化，顶部、中部和底部的花的化学​​谱显示出+/-20%的量级差异（或更多），这明显超出了典型药品的公差 =+/-10%，这在 C.Sativa 被视为药品时造成了主要的一致性和分级问题。这里，与我们的行业合作伙伴 Glass Pharms Ltd 合作。 ，我们的目标是通过多种途径解决这个问题，通过筛选不同的 C. Sativa 种质，我们将建立植物结构变异，目的是探索最终创造具有改变结构的 C. Sativa 植物的潜力：减少“圣诞节”。 “树”形和更多的“烛台”形状，花序（花朵）更均匀地呈现出入射光变化。这应该对花朵生物活性成分的组成产生积极影响，重要的是减少。我们还将寻求提高生产力并减少矮化C .Sativa 通过既定方法并通过垂直农业探索完全受控环境农业的潜力，这种对环境的绝对控制将使我们能够在作物发育过程中充分利用 VF 嵌入式灯的可调光强度和波长。也有机会“调整”大麻素和萜类化合物的含量、组成和变异与此相关，我们将阐明基因和代谢物水平上的光/植物相互作用，以确定重要的基因级联，从而确定基因目标/标记。未来通过传统或现代（基因改造/基因编辑）育种方法进行开发。作为 JHI 和 Glass Pharms Ltd（两家高 TCH 大麻生产许可证持有者）之间合作的一部分，我们将提供以下服务：提高大麻中所含活性药物成分在同一植物不同花序（花）中分布的一致性。CAE/VF 系统的品种表型更好标准化，目标是矮化和均匀表型。明确的操作条件和过程/定义大麻素含量和成分 在更广泛的背景下，计划中的研究支持了英国在高价值行业经济增长和相关永久性高技能工作、改善医疗保健方面的许多政策目标。不断变化的人口结构和英国农业基础的多样化，这里提出的科学将巩固并帮助维持英国作为药用大麻生产和出口的领先地位。